Skip to main content
IOBT
NASDAQ Life Sciences

IO Biotech Files for Chapter 7 Bankruptcy, Ceases Operations, and Terminates All Staff

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
10
Price
$0.161
Mkt Cap
$12.404M
52W Low
$0.14
52W High
$2.79
52W Position info
15% above low
Off High info
94% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

IOBT is trading near its 52-week low of $0.14 (15% above the low) on light trading volume (0.1× avg).

Summary

IO Biotech, Inc. has filed for Chapter 7 bankruptcy, ceasing all operations and terminating its board and executive team, indicating a likely total loss for common stockholders.


Key Events · Legal and Risk Events · IOBT

  • Chapter 7 Bankruptcy Filing

    IO Biotech, Inc. ceased operations and filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code, initiating liquidation.

  • Shareholder Impact Warning

    The company stated it is unlikely that holders of its common stock will receive any payment or distribution from the bankruptcy proceedings.

  • Complete Leadership Departure

    All members of the Board of Directors resigned, and all employees and officers, including the CEO and CFO, were terminated concurrently with the bankruptcy filing.

  • Debt Default Triggered

    The Chapter 7 filing triggered an event of default under a finance contract with the European Investment Bank, allowing demand for immediate repayment of €22.5 million.


Analysis · IOBT · Life Sciences

This 8-K filing announces IO Biotech, Inc.'s voluntary petition for Chapter 7 bankruptcy, signifying a complete liquidation of assets. The filing explicitly states that common stockholders are unlikely to receive any distribution. Concurrently, all directors resigned, and all employees and officers, including the CEO and CFO, were terminated. The bankruptcy also triggers an immediate default on a €22.5 million debt to the European Investment Bank. The company will no longer file periodic reports with the SEC. This event represents a complete failure of the business and a near-total loss for equity investors.

At the time of this filing, IOBT was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4M. The 52-week trading range was $0.14 to $2.79. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IOBT - Latest Insights